Five issued U.S. patents give Caring Brands Inc. (Nasdaq: CABR) a defined legal perimeter around its two flagship products as of August 6, 2026. The read-through for the company's licensing-led model is straightforward: that patent portfolio strengthens the hand in partner negotiations across markets the company sizes at more than $20 billion combined. What the patents cannot fix is an open Nasdaq delisting proceeding, which places the company's listed status in question at the same moment it is trying to attract global licensees.
A four-plus-one patent structure
Four patents cover Hair Enzyme Booster, a topical product designed to work alongside minoxidil by targeting low baseline scalp enzyme levels. Caring Brands says 50% to 60% of minoxidil users fail to see optimal results because of those low levels. The four-patent family protects compositions and methods relating to sulfotransferase enzyme activity and minoxidil metabolism, and the company sizes the addressable market at $1.8 billion, citing more than 80 million hair loss sufferers in the United States alone.
The fifth patent covers Photocil, a narrow-band UV filter engineered for targeted skin health applications. Its market framing spans global patient populations of more than 125 million psoriasis sufferers and 100 million vitiligo sufferers, set against a global dermatology market the company sizes at more than $20 billion. Additional U.S. and international applications remain in active prosecution across multiple countries.
Commercialization strategy and the Taisho relationship
Caring Brands is pursuing a hybrid commercial model. The primary channel is B2B licensing, building on existing agreements including one with Taisho Pharmaceutical. Secondary distribution runs through Amazon and select retail channels. Chief Executive Officer Dr. Glynn Wilson said the company's immediate operational focus is translating its legal foundation into scalable commercial opportunities and securing new licensing agreements globally. Preparations underway include third-party manufacturing coordination, packaging and labeling alignment, and the assembly of diligence materials for prospective regional distributors.
The counterargument
The Nasdaq compliance situation is the objection that carries the most weight. Caring Brands disclosed it is not in compliance with the stockholders' equity requirement under Nasdaq Listing Rule 5550(b). The Nasdaq Staff issued a delisting determination and the company has appealed to a Hearings Panel, but there is no assurance that appeal will succeed or that its securities will remain listed. For a company actively courting major licensing partners, a loss of Nasdaq listing would affect both visibility and capital access in ways the patent portfolio cannot compensate for.
The company's own filing notes that patent issuance does not constitute regulatory approval, establish clinical efficacy, or guarantee commercial success. On balance, five patents across two platforms represent a real legal asset. Whether that asset translates into revenue depends, in part, on what the Hearings Panel rules on the delisting appeal.